Dr. Rachel Liberatore, PhD will be representing our team at the BIO CEO & Investor Conference in New York today and tomorrow! This is a fantastic opportunity for Renbio to showcase our innovative work in the biotech industry and connect with other leaders and investors in the field. If you're attending, we'd love the opportunity to connect and share insights! Stay tuned for updates on our latest developments. #Renbio #BIOCEOInvestorConference #BiotechInnovation https://bcic.bio.org/about
RenBio’s Post
More Relevant Posts
-
We hope to see you in New York around the BIO CEO & Investor Conference -- one of the largest investor conferences in our industry where institutional investors, industry analysts, and senior executives are shaping the future investment landscape of biotechnology -- on February 26th and 27th. If you'll be in the city at the same time and are interested in improving translational success, accelerating project timelines, and reducing development costs of in-vivo studies, reach out over LinkedIn or to hello [at] modernvivo.com. #bioceo24 #invivo #drugdiscovery #preclinicalresearch #preclinical
-
-
SFBN Feed: This is the TLDR of JPM Day 1 https://lnkd.in/gwMgHAk5 In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San… Click here to view original [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
This is the TLDR of JPM Day 1
https://sfbn.org
-
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, PhD, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3ZpyKye #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
-
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3t9q3ff #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
-
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3PKwoXs #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
-
Associate Director - Investments at Oppenheimer & Co. Inc Portfolio Manager Omega Portfolio Management
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3EP4KCm #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
-
Financial Advisor - Investments at The Princeton Sharpe Group of Oppenheimer & Co. Inc.
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3ZpTMNk #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
Executive Coach / Leadership Development Advisor focusing on life sciences and biotech
5moFantastic! It's going to be a terrific conference. Love seeing RenBio in the showcase.